AstraZeneca has vowed to spend over $10 billion on R&D deals in Asia, focusing on China, amid ongoing fraud scandal ...

The new centre will focus on early-stage research and clinical development, supported by data science and AI labs.

AstraZeneca (LSE:AZN) has seen a shift recently with the EU approval of ENHERTU® and Imfinzi®, which are likely influential ...

The British-Swedish drug maker, which saw one of its executives detained in China last year, announced a multibillion-dollar ...

British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China.

AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker ...

Multinational pharmaceutical company AstraZeneca is bullish about China's role as a global innovation powerhouse, underpinned ...

The investments come amid an ongoing insurance fraud probe into AstraZeneca’s former China head Leon Wang—and despite ...

Cambridge-headquartered AstraZeneca is investing $2.5 billion in Beijing to establish its sixth global strategic R & D centre ...

Investment includes agreements with Harbour BioMed, Syneron Bio and BioKangtai
.

US pharmaceutical giant Pfizer's new research and development (R&D) centre officially opened at BioPark in the Beijing Economic-Technological ...

HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the ...